Langxin Qisheng

Langxin Qisheng is a clinical-stage biotechnology company based in Suzhou, China, specializing in the development of innovative Adeno-Associated Virus (AAV) gene therapies. The company focuses on addressing unmet medical needs in ophthalmology, including inherited retinal diseases and chronic conditions like age-related macular degeneration. Its lead candidate, LX101, is a gene therapy targeting RPE65-mediated Leber Congenital Amaurosis and has progressed into Phase 1/2 clinical trials. Langxin Qisheng operates a proprietary platform that integrates vector design, optimization, and large-scale GMP manufacturing capabilities. The company is supported by a strong syndicate of investors, including Lilly Asia Ventures and IDG Capital, to advance its diverse pipeline of genetic medicines.